Their findings indicate that Body Mass Index (BMI) , a statistical measure that scales weight to height , provides an indicator for one's risk of developing multiple myeloma, a cancer of the blood cells that produce antibodies. Multiple myeloma currently affects more than 50,000 people in the U.S., and the five-year survival rates of the cancer are below 40 percent.

The study, published in the July issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, takes its data from over 100,000 participants in the on-going Nurses, Health Study and Health Professionals Follow-up Study, two similar large-scale studies. The study findings were similar to those from previously published studies that included smaller numbers of multiple myeloma patients, and/or were based on a one-time recording of height and weight.

"I find the results of these studies encouraging, since they show consistent results about the first risk factor for multiple myeloma that people can actually modify," said the study's lead author Brenda M. Birmann, Sc.D., a researcher in the Department of Medicine at Brigham and Women's Hospital and Harvard Medical School. "Treatment options for this disease are improving, but it is also important to identify risk factors that could be modified. We would like to learn how to prevent its occurrence."

The Brigham and Women's Hospital-based Nurses, Health Study has followed the health of female registered nurses since 1976, and the Health Professionals Follow-up Study, based at Harvard School of Public Health, has followed males from several health professions since 1986. These studies recorded height, weight and physical activity for each person enrolled, as well as diet, medications, smoking habits and other health behaviors, and has updated that information every two to four years. Of the 136,623 participants who qualified for their study protocol, Birmann and her colleagues confirmed 215 cases of multiple myeloma.

Body Mass Index (BMI) is computed by dividing a person's weight by the square of their height. A BMI between 18.5 and 25 is considered optimal, a BMI of 25-29 is considered overweight, and a BMI of 30 or higher is considered obese.

The association between BMI and multiple myeloma was strongest among men with a BMI of 30 or more. When compared with leaner men (those with a BMI below 22), obese men, the researchers said, were over twice as likely to develop multiple myeloma. The effect was less pronounced among overweight or obese women, yet those women also had an increased risk.

The study also looked at whether regular exercise is related to risk of multiple myeloma. There was not a clear effect of exercise on risk, although the results among women suggested that those who exercise more might have a lower risk. "We cannot say with certainty that exercise reduces the risk of multiple myeloma, but there is ample evidence that regular exercise offers many other health benefits," Birmann said.

The study findings do show, however, that the effect of BMI on risk of multiple myeloma is separate from any possible effect of physical activity.

According to Birmann, previous research has identified possible biological links between obesity and multiple myeloma. For example, adipocytes, cells found in fat tissue, produce a cell signal, called interleukin-6 (IL-6), which promotes the immune system's inflammation response. In obese people, this can cause an overproduction of IL-6, which in turn creates a cellular environment that sustains multiple myeloma. "The IL-6 chemical pathway is one possible way obesity could influence the risk of developing diseases like cancer or cardiovascular disease, but the answer might also lie in other relationships between obesity and cancer," Birmann said.

Further research, she said, will uncover more about the relationships between obesity and cancers such as multiple myeloma. The researchers believe their findings may lead to examination in greater detail of the BMI/multiple myeloma link, including the role of IL-6 and other chemical signals, energy metabolism, and other risk factors such as weight change or weight cycling.

aacr

Tag Cloud

Order Adalat Without Prescription
Order Aldactone Without Prescription
Order Altace Without Prescription
Order Atenolol Without Prescription
Order Avalide Without Prescription
Order Avapro Without Prescription
Order Azor Without Prescription
Order Benicar Without Prescription
Order Betapace Without Prescription
Order Caduet Without Prescription
Order Captopril Without Prescription
Order Cardura Without Prescription
Order Clonidine Without Prescription
Order Co-Diovan Without Prescription
Order Cordarone Without Prescription
Order Coreg Without Prescription
Order Coversyl Without Prescription
Order Cozaar Without Prescription
Order Diltiazem HCL Without Prescription
Order Diovan Without Prescription
Order Hydrochlorothiazide Without Prescription
Order Hytrin Without Prescription
Order Hyzaar Without Prescription
Order Inderal Without Prescription
Order Isosorbide Mononitrate Without Prescription
Order Lanoxin Without Prescription
Order Lasix Without Prescription
Order Lipitor Without Prescription
Order Lotensin Without Prescription
Order Lotrel Without Prescription
Order Lozol Without Prescription
Order Micardis Without Prescription
Order Minipress Without Prescription
Order Nebivolol Without Prescription
Order Norvasc Without Prescription
Order Plavix Without Prescription
Order Pletal Without Prescription
Order Prinivil Without Prescription
Order Rosulip-F Without Prescription
Order Toprol XL Without Prescription
Order Torsemide Without Prescription
Order Trandate Without Prescription
Order Trental Without Prescription
Order Triamterene Without Prescription
Order Tricor Without Prescription
Order Vasotec Without Prescription
Order Vastarel Without Prescription
Order Verapamil Without Prescription
Order Zebeta Without Prescription
Order Zestoretic Without Prescription